Skip to main content

FDA Approves Symvess, an Acellular Tissue-Engineered Vessel

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 2, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, Jan. 2, 2025 -- The U.S. Food and Drug Administration has approved Symvess, the first acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to prevent imminent limb loss.

Symvess is a sterile, acellular tissue-engineered vessel composed of extracellular matrix proteins usually found in human blood vessels and is manufactured using human vascular smooth muscle cells derived from human aortic tissue. The one-time, single-use product is implanted surgically to replace a patient's damaged blood vessel after traumatic injury to the extremity.

The safety and effectiveness of Symvess was assessed in a prospective, single-arm, multicenter study involving 54 patients with life- or limb-threatening vascular trauma. Of the 54 patients, 36 (67 percent) and 39 patients (72 percent), respectively, retained primary patency (blood flow present without any intervention) and secondary patency (at least one intervention required to maintain blood flow) at 30 days after implantation. Five and eight patients underwent amputation of the treated limb within the first 30 days and by the end of study (month 36), respectively.

"Today's decision to approve a new therapeutic product based on novel medical technology represents important progress in addressing a significant unmet medical need," Nicole Verdun, M.D., director of the Office of Therapeutic Products in the FDA Center for Biologics Evaluation and Research, said in a statement.

Approval of Symvess was granted to Humacyte Global.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Study IDs Predictors of Biomechanical Function in Patients With OA Undergoing Hip Replacement

WEDNESDAY, April 23, 2025 -- For patients undergoing total hip arthroplasty (THA), osteoarthritis (OA) severity is the best predictor of preoperative biomechanical function, and...

Preop Macular Thickness May Be Marker of Postop Delirium in Seniors

FRIDAY, April 4, 2025 -- In older patients undergoing surgery, preoperative macular thickness may be a marker for vulnerability to developing postoperative delirium, according to...

NeuroSAFE Improves Erectile Function After Radical Prostatectomy

THURSDAY, April 3, 2025 -- Use of the NeuroSAFE technique, a standardized frozen section analysis that enables accurate real-time detection of positive surgical margins during...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.